Recent News for BRPA - Big Rock Partners Acquisition Corp.

Date Title
Apr 7 Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal
Apr 6 NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
Mar 29 63 Biggest Movers From Friday
Mar 29 NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
Mar 26 NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
Mar 15 Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination
Mar 12 SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations
Mar 9 NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Feb 26 SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations
Feb 23 NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
Feb 19 SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations
Feb 12 SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, BRPA and KTYB Shareholders About Its Ongoing Investigations
Feb 9 Mid-Day Market Update: KalVista Pharmaceuticals Jumps Following Positive HAE Readout; Ekso Bionics Shares Slide
Feb 9 70 Stocks Moving In Tuesday's Mid-Day Session
Feb 9 NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
Feb 9 NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19
Feb 7 Lifshitz Law Firm, P.C. Announces Investigation of BRPA, CGRO, GXGX, HEC, FSRV, LCY, STPK, TPGY and VSPR
Feb 5 SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, and BRPA Shareholders About Its Ongoing Investigations
Jan 29 SHAREHOLDER ALERT: WeissLaw LLP Reminds JWS, BRPA, and UROV Shareholders About Its Ongoing Investigations
Jan 22 SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, BRPA, and ZAGG Shareholders About Its Ongoing Investigations
Jan 14 SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, FIII, JWS and BRPA Shareholders About Its Ongoing Investigations
Jan 11 NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
Jan 7 SHAREHOLDER ALERT: WeissLaw LLP Reminds FIII, JWS, BRPA, and CGIX Shareholders About Its Ongoing Investigations
Dec 31 SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Big Rock Partners Acquisition Corp. - BRPA
Dec 30 NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
Back to the Main BRPA Page...